Beclomethasone and Salbutamol — Competitive Intelligence Brief

Beclomethasone and Salbutamol (Beclomethasone and Salbutamol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA). Area: Respiratory / Pulmonology.

marketed Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol) Respiratory / Pulmonology Small molecule

Target snapshot

Beclomethasone and Salbutamol (Beclomethasone and Salbutamol) — University of Calgary. This combination inhaler delivers a corticosteroid (beclomethasone) to reduce airway inflammation and a short-acting beta-2 agonist (salbutamol) to rapidly relieve bronchospasm.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Beclomethasone and Salbutamol TARGET	Beclomethasone and Salbutamol	University of Calgary	marketed	Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA)	Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol)
BDP/salbutamol HFA pMDI	BDP/salbutamol HFA pMDI	Chiesi Farmaceutici S.p.A.	phase 3	Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA)	Glucocorticoid receptor (BDP); Beta-2 adrenergic receptor (salbutamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) class)

1. Chiesi Farmaceutici S.p.A. · 1 drug in this class
2. University of Calgary · 1 drug in this class